Learning Objectives 10/26/2017. New Treatments in Atopic Dermatitis
|
|
- Merryl Robertson
- 5 years ago
- Views:
Transcription
1 New Treatments in Atopic Dermatitis Lynda C. Schneider, MD Professor of Pediatrics, Harvard Medical School Boston Children s Hospital lynda.schneider@childrens.harvard.edu Disclosures: Lynda Schneider, MD Investigator Astellas (Protopic topical tacrolimus), Regeneron (Dupilumab) Grants Food Allergy Research & Education (FARE), Genentech, DBV Technologies, NIH/NIAID/DAIT (Atopic Dermatitis Vaccinia Network, Atopic Dermatitis Research Network, ADRN2) Pharmaceutical Advisory Board Pfizer (Crisaborole) Advisory Boards FARE Learning Objectives Upon completion of this session participants should be able to: Evaluate new therapies for atopic dermatitis 1
2 Pillars of AD therapy Dry skin Inflammation Infection Itching Identify Triggers Dry Skin Care - Moisturizers Ref. Lucky AW et al Pediatr Derm 1997 Szczepanowska J et al Ped Allergy Immunol 2008 Van Zuuren EJ et al British J Derm 2017 doi: /bjd15602 Steroid sparing Improve xerosis & pruritus Patient/family preference - Ointments best, no lotions Absence of fragrance, dyes, food Time of day Age Pillars of atopic dermatitis therapy Repair Barrier Moisturize Inflammation Infection Itching Identify Triggers 2
3 Streamlined severity based treatment model Practical suggestions for treatment plans MILD DISEASE Basic Management Skin care Antiseptic measures Trigger avoidance Algorithm for Care of Atopic Dermatitis MODERATE TO SEVERE DISEASE Maintenance (Proactive) TCI (pimecrolimus/tacrolimus) TCI 2 3 x weekly OR if patient is non responsive 1 2 x daily Maintenance (Proactive) TC Medium potency TC (Class III IV) 1 2 x weekly (except for face/eyes) AND/OR Low potency TC (Class V VII) 1 2 x daily (including face/eyes) Acute Treatment Topical antiinflammatory applied to inflamed skin Low potency TC (Class VII) bid for up to 3 days beyond clearance Modified from Eichenfield LF et al. Pediatrics 2015; 136(3): For relapsing course (frequent/persistent flares despite treatment) TC at first signs/symptom or maintenance Acute Treatment Topical anti inflammatory applied to inflamed skin Medium potency TC (Class III IV) bid for up to 3 days beyond clearance Flare not resolved in 7 days Consider nonadherence, infection, misdiagnosis Step wise Treatment Algorithm Recalcitrant moderate to severe AD Systemic immunosuppressive/ immunomodulatory (e.g. CSA, AZA, MTX, MMF, Dupilumab**) or UV therapy Moderate AD Activity of disease Mid high potency TCS &/or TCI*, Proactive TCS or TCI, Wet wraps Mild AD Low mid potency TCS and/or TCI * or Crisaborole * Basic treatment: Skin hydration, moisturizers, bleach baths, avoidance of irritants and triggers Adapted from Akdis CA et al. J Allergy Clin Immunol 2006;118:
4 Dupilumab blocks the IL 4/IL 13 receptor/ligand system Type I Receptor B cells, T cells, Monocytes, Eosinophils, Fibroblasts Type II Receptor Epithelial cells, Smooth muscle cells, Fibroblasts, Monocytes, Activated B cells Phase III Study Design: SOLO 1 and SOLO 2 Objective: Assess efficacy and safety of dupilumab monotherapy vs. placebo in adults with moderate to severe AD SOLO 1: 671 patients SOLO 2: 708 patients Identical study design (randomized, double blind, placebo controlled, parallel group) Loading dose on Day 1 * Treatment period (16 weeks) Follow up period (12 weeks) Day 35 to 1 Baseline Week 16 Week 28 Screening R Placebo SC qw Dupilumab 300 mg SC q2w Dupilumab 300 mg SC qw Post treatment options: Maintenance study Open label extension Safety follow up through week 28 *Dupilumab, 600 mg; placebo, matching placebo; q2w, every other week; qw, weekly; R, randomization; SC, subcutaneously. Simpson EL et al. N Engl J Med 2016; 375: Primary End Point and Key Secondary End Point Simpson EL et al. N Engl J Med 2016;375:
5 Secondary End Points Simpson EL et al. N Engl J Med 2016;375: Simpson EL et al. N Engl J Med 2016; 375: Conclusions from Phase III Dupilumab Trials Both dose regimens of dupilumab showed clinically meaningful improvement and statistical significance vs. placebo in: AD signs & symptoms (including itch/pruritus and sleep) Health related quality of life Symptoms of anxiety/depression Most AEs were mild or moderate Injection site reactions and conjunctivitis were more frequent with dupilumab Fewer skin infections in dupilumab group Simpson EL et al. N Engl J Med 2016; 375: Considerations for Prescribing Dupilumab Hypersensitivity reactions - Urticaria - Serum sickness or serum sickness like reactions reported 2/1472 subjects Patients should not adjust/stop their asthma treatments without consultation with their physicians. Patients with known helminth infections were excluded from participation in clinical studies. Avoid live viral vaccines. Ref: Package Insert 5
6 Prescribing Dupilumab Conjunctivitis should be promptly treated Can be used with topical steroids Topical calcineurin inhibitors may be used, but reserved for problem areas only, such as the face, neck, intertriginous and genital areas. Missed doses - within 7 days, administer & resume the patient s original schedule. - > 7 days, skip dose and give next dose on the original schedule. Ref: Package Insert Brunner, Guttman Yassky, Leung. J Allergy Clin Immunol;139:S65 76 Copyright 2017 American Academy of Allergy, Asthma & Immunology Selected Systemic Agents Agent Target Phase Comments Tralokinumab IL 13 3 Phase 3 in progress Lebrikizumab IL 13 2 Phase 2 completed; Phase 2b planned Nemolizumab IL 31RA 2 Phase 2 published NEJM; dose ranging study in progress. Ustekinumab IL 12/IL23 2 Approved for psoriasis. Missed primary endpoint in AD in 2 studies.* Tezepelumab TSLP 2 Phase IIa completed Secukinumab IL 17 2 Approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis References: Brunner, Guttman Yassky, Leung. J Allergy Clin Immunol 2017;139:S65 76; Clinicaltrials.gov 9/1/17 *Khattri, Brunner, et al. Exp Dermatol 2017;26(1):28 35; 6
7 PDE 4 inhibitors for Atopic Dermatitis Topical PDE 4 inhibitors Crisaborole ointment approved Roflumilast (cream) RVT 501 (ointment) OPA (ointment) E6005 (ointment) Oral PDE 4 Inhibitor Apremilast (approved for psoriasis; development stopped) Figure from the Pharmaceutical Journal and Clinical Pharmacist 23 FEB 2017 Phase III trials Crisaborale Paller AS et al. J Am Acad Dermatol 2016;75: Primary Endpoint Percent of patients achieving ISGA clear or almost clear Paller AS et al. J Am Acad Dermatol 2016;75:
8 Percent of Patients Achieving Improvement in Pruritus Paller AS et al. J Am Acad Dermatol 2016;75: JAK STAT signaling as Fig a therapeutic 2 target Paller AS, Kebashima K, Bieber T. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright 2017 American Academy of Allergy, Asthma & Immunology Copyright 2017 American Academy of Allergy, Asthma & Immunology Agent Target Route Comments Upadacitinib (ABT 494) JAK inhibitors in development for AD JAK 1 oral Met primary endpoint in Phase 2b study. Phase 3 planned for Baricitinib JAK 1/2 oral Phase 2 completed PF JAK 1 oral Phase 2 LEO Jak 1/3 oral Phase 2 trials in Japan Tofacitinib Jak 1/3 topical Phase 2a done; development stopped. Oral approved for RA & has risk of serious infections. Ruxolitinib, INCB JAK 1/2 topical Phase 2 Brunner P, Guttman Yassky E, Leung DYM. J Allergy Clin Immunol 2017;139:S Clinicaltrials.gov 9/1/17 Paller AS, Kebashima K, Bieber T. J Allergy Clin Immunol 2017;140: Abbvie Data on file. Upadacitinib AD Phase 2b Press Release 05SEPT2017 8
9 Phase 2b Results for Oral Upadacitinib (ABT 494) Abbvie Data on file. Upadacitinib AD Phase 2b Press Release 05SEPT2017 Pillars of atopic dermatitis therapy Repair Barrier Moisturize Inflammation Infection Itching Identify Triggers Dysbiosis of the skin microbiome in AD is associated with S. aureus colonization Nakatsuji T et al., Sci Transl Med 2017; 9, eaah4680 9
10 Lack of antimicrobial activity in CoNS in Atopic Dermatitis Nakatsuji T et al., Sci Transl Med 2017; 9, eaah4680 Autologous Transplantation of Antimicrobial CoNS Reduces Survival of S. aureus Nakatsuji T et al., Sci Transl Med 2017; 9, eaah4680 Pillars of atopic dermatitis therapy Repair Barrier Moisturize Inflammation Infection Itching Identify Triggers 10
11 Antihistamines.evidence based review of 16 controlled studies revealed little objective evidence demonstrating the relief of pruritus when sedating or non sedating antihistamines were used in the treatment of AD. Reduction of skin inflammation with will often reduce pruritus. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, et al. J Allergy Clin Immunol Feb; 131: H4R antagonist ZPL (oral) Phase 2a NK1R antagonists (oral) VLY 686/tradipitant Serlopitant TPRV1 Channel Antagonist PAC (cream) ANTI ITCH THERAPIES Paller AS, Kebashima K, Bieber T. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright 2017 American Academy of Allergy, Asthma & Immunology The clinician should recognize that AD has a significant impact on quality of life and patients have an increased risk for psychological distress. Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, et al. J Allergy Clin Immunol Feb; 131:
12 The clinician should assess for sleep disturbances. Optimize sleep hygiene Treat AD inflammation aggressively to improve sleep and itching Refer to psychologist or sleep specialist if needed Schneider L, Tilles S, Lio P, Boguniewicz M, Beck L, et al. J Allergy Clin Immunol Feb; 131: Improve Adherence Educate patients about AD & demonstrate skin care Give patients a written plan and assess understanding of skin care plan Develop a skin care schedule Assess concerns about medications Assess barriers What are the hardest parts for you/your child to follow? What parts do you skip/miss the most? Chou J et al. Allergy and Asthma Proceedings. 2011;32(5): English.pdf 12
13 Rea, Corinna, et al. Pediatric Academic Societies Meeting, May, Summary Treat dry skin, Inflammation, Infection, Itching & Identify triggers Dupilumab and Crisaborale are two recently approved new therapies for AD Acknowledgements BCH AD Program Wendy Elverson, RD Jennifer LeBovidge, PhD Karol Timmons, RN, PNP Division of Immunology Raif S. Geha, MD Hans Oettgen, MD, PhD Janet Chou, MD Steve Gellis, MD Marilyn Liang, MD Jennifer Huang, MD 13
14 Thank you for your attention Enjoy Boston! 14
An Update on Topical Therapy for Atopic Dermatitis
An Update on Topical Therapy for Atopic Dermatitis Amy S. Paller, M.D. Professor and Chair of Dermatology Professor of Pediatrics Northwestern University Feinberg School of Medicine Chicago, Illinois Disclosures
More informationBiologic Therapies for Atopic Dermatitis and Beyond
Biologic Therapies for Atopic Dermatitis and Beyond Jonathan Corren, M.D. Departments of Medicine and Pediatrics, David Geffen School of Medicine at UCLA Disclosures Genentech - research Medimmune/AZ -
More informationAtopic Dermatitis: Emerging therapies. Melinda Gooderham MSc MD FRCPC
Atopic Dermatitis: Emerging therapies Melinda Gooderham MSc MD FRCPC SKiN Centre for Dermatology, Peterborough Assistant Professor, Queen s University, Kingston ON Investigator, Probity Medical Research,
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August
BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review
More informationPositioning New Treatments for Atopic Dermatitis in Our Practice Parameter
40 th Annual Pulmonary and Allergy Update Positioning New Treatments for Atopic Dermatitis in Our Practice Parameter Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics
More informationOverview. Atopic Dermatitis. Overview. 1. Genes and pathogenesis 2. Natural history and disease course 3. Comorbidities 4. Treatments 5.
Overview Atopic Dermatitis Albert C. Yan, MD, FAAP, FAAD Children s Hospital of Philadelphia Perelman School of Medicine at the University of Pennsylvania 1. Genes and pathogenesis 2. Natural history and
More informationAssessing the Current Treatment of Atopic Dermatitis: Unmet Needs
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationA Yardstick for Managing Patients with Atopic Dermatitis
AAIFNA 2018 Symposium A Yardstick for Managing Patients with Atopic Dermatitis Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University
More informationLawrence F. Eichenfield, M.D.
What s New in Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence F.
More informationThe Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis
The Role of Allergen Immunotherapy and Biologicals in the Treatment of Atopic Dermatitis John Oppenheimer MD Div Allergy and Immunology UMDNJ-Rutgers Potential Conflicts of Interest Consultant GSK, Teva,
More informationTopical Immunomodulator Step Therapy Program
Topical Immunomodulator Step Therapy Program Policy Number: 5.01.557 Last Review: 8/2017 Origination: 7/2013 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) BCBSKC will provide
More informationWhat s Topical About Topicals?
What s Topical About Topicals? Megha M. Tollefson, MD Associate Professor of Dermatology and Pediatrics July 29, 2017 2015 MFMER 3513105-1 Disclosures None 2015 MFMER 3513105-2 Outline Topical steroids
More informationWhat s New in Atopic Dermatitis?
What s New in Atopic Dermatitis? SMITA AWASTHI, MD ASSISTANT CLINICAL PROFESSOR, DEPT. OF DERMATOLOGY AND PEDIATRICS UNIVERSITY OF CALIFORNIA, DAVIS Disclosures No financial disclosures relevant to this
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017
More informationAtopic Derma--s & Psoriasis Highlights. Ian McDonald Dermatology SpR
Atopic Derma--s & Psoriasis Highlights Ian McDonald Dermatology SpR Atopic derma66s Pathophysiology Associated morbidity Topical therapy Systemic therapy Crisaborole PDE4 inhibitor Primary endpoint: Success
More informationManaging Atopic Derma00s: Itching the Night Away. Karol Timmons RN, MS, CPNP Boston Children s Hospital Atopic Derma00s Center
Managing Atopic Derma00s: Itching the Night Away Karol Timmons RN, MS, CPNP Boston Children s Hospital Atopic Derma00s Center Learning Objec-ves Describe common treatments for atopic derma00s including:
More informationMedication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017
More informationItchy babies: Current treatment guidelines for atopic dermatitis
Itchy babies: Current treatment guidelines for atopic dermatitis Rachel Laarman, MD Helen DeVos Children s Hospital Grand Rapids, MI Photo cred: www.dermatologytimes.modernmedicine.com I have no disclosures
More informationExpert Analysis of Emerging Atopic Dermatitis Therapy Studies. A CE/CME Activity
Expert Analysis of Emerging Atopic Dermatitis Therapy Studies Overview A CE/CME Activity Lawrence F. Eichenfield, MD, and Jonathan I. Silverberg, MD, PhD, MPH, provide their perspectives on the clinical
More informationRecalcitrant Warty Erythroderma With Severe Pruritus. Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University
Recalcitrant Warty Erythroderma With Severe Pruritus Gil Yosipovitch Professor & Chair Department of Dermatology & Itch Center Temple University DISCLOSURE OF RELEVANT RELATIONSHIPS WITH INDUSTRY Gil Yosipovitch,
More informationUPDATES IN ATOPIC DERMATITIS
UPDATES IN ATOPIC DERMATITIS Amanda Hess, MMS, PA-C President-Elect, AAPA-AAI Arizona Asthma and Allergy Institute, Scottsdale, AZ LEARNING OBJECTIVES Discuss epidemiology, risk factors, and causes of
More informationAtopic Dermatitis Guidelines: What s New?
Atopic Dermatitis Guidelines: What s New? Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Anacor/Pfizer Genentech
More informationLessons Learned from the International Eczema Council (IEC)
Lessons Learned from the International Eczema Council (IEC) Amy S. Paller, MD Northwestern University Feinberg School of Medicine American Academy of Dermatology meeting F046 February 17, 2017 No conflicts
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAtopic Eczema with detail on how to apply wet wraps
Atopic Eczema with detail on how to apply wet wraps Dr Carol Hlela Consultant Dermatologist Head of Unit, Department of Dermatology, Paediatrics Red Cross Children s Hospital, UCT Red Cross War Memorial
More informationManaging and Minimizing Flare-ups in Atopic Dermatitis
Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology
More informationNote: AD stands for Atopic Dermatitis. Page numbers in italics indicate figures. Page numbers followed by a t indicate tables.
index Note: AD stands for Atopic Dermatitis. Page numbers in italics indicate figures. Page numbers followed by a t indicate tables. Adolescent-onset AD, 67, 70, 71 ADSI (AD Severity ), 101 Adult-onset
More informationUniversity Medical Center Utrecht, Utrecht, Netherlands; 2 University of Lübeck, Lübeck, Germany; 3
Dupilumab With Concomitant Topical Corticosteroids in Adult Patients With Atopic Dermatitis who are not Adequately Controlled With or are Intolerant to Cyclosporine A, or When This Treatment is Medically
More informationHelp! What s the Answer? FRM F027 - Translating Evidence into Practice: Atopic Dermatitis Guidelines
Help! What s the Answer? FRM F027 - Translating Evidence into Practice: Atopic Dermatitis Guidelines Christine T. Lauren, M.D. Assistant Professor of Dermatology and Pediatrics Columbia University, New
More informationBeacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care
Beacon Hospital Annual Study Morning Treatment of Atopic Dermatitis (Eczema) in Primary Care Alan D. Irvine MD DSc Lecture overview What causes AD How to get optimise results in primary care Eczema and
More informationDISCLOSURES WHAT S NEW AND EXCITING FROM JAAD
WHAT S NEW AND EXCITING FROM JAAD Bruce H. Thiers, MD, Editor, JAAD Professor, Medical University of South Carolina Department of Dermatology and Dermatologic Surgery DISCLOSURES PFIZER VALEANT EFFECT
More informationWYNNIS L. TOM, MD: And I m Dr. Wynnis Tom. I m Associate Professor of Dermatology and Pediatrics at the University of California, San Diego.
LEARNING OBJECTIVES At the conclusion of this activity, participants should be better able to: Assess the severity of atopic dermatitis (AD) and its impact on the patient Evaluate treatment efficacy Design
More informationThe Burden of Atopic Dermatitis: from Population to Bedside
The Burden of Atopic Dermatitis: from Population to Bedside S028 AAD Annual Meeting March 2, 2019 Research and institutional funding Sanofi Regeneron Disclosures Consultant Honoraria Sanofi Astellas Canada
More information6/19/18. Emerging Challenges in Primary Care: Atopic Dermatitis: New Insights, New Therapies. Faculty. Disclosures
Emerging Challenges in Primary Care: 2018 Atopic Dermatitis: New Insights, New Therapies 1 Faculty Brad P. Glick, DO, MPH, FAOCD Director, South Florida Psoriasis Treatment Centers Clinical Assistant Professor
More informationHeld in conjunction with AMCP Managed Care & Specialty Pharmacy Annual Meeting Jointly provided by
Jointly provided by This activity is supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals Held in conjunction with AMCP Managed Care & Specialty Pharmacy Annual
More informationPNW EPC Drug Effectiveness Review Project Summary Report Atopic Dermatitis New Drug Evaluation: Dupilumab
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationUpdate on emollients
Update on emollients Amal Mhanna, MD Pediatric Dermatologist Clemenceau Medical Center Disclosure: I was a member of an advisory board y for J&J and received honoraria. Emollients and moisturizers are
More informationThe safety and effectiveness of Dupixent in pediatric patients have not been established (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa
More informationNovel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript
Novel Insights in Atopic Dermatitis: Pathways, Biomarkers, and Phenotypes for a Targeted Approach Transcript Title Slide Welcome to the CME-certified program: Novel Insights in Atopic Dermatitis; Pathways,
More informationPediatric Inflammatory Skin Disease Update. Inflammatory Skin Diseases. Factors influencing development of atopic dermatitis.
Pediatric Inflammatory Skin Disease Update Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics Rady Children s Hospital, San Diego University of California, San Diego Disclosure Lawrence
More information15 minute eczema consultation
THERAPY WORKSHOP 15 minute eczema consultation History Current treatments Examination Treatment Plan Written action plan Soap substitute/bath oil Antiseptic baths Emollients Topical steroids Other treatments
More informationEucrisa. Eucrisa (crisaborole) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)
More informationWhat is atopic dermatitis?
What is atopic dermatitis? Complex inflammatory skin disorder intense pruritus cutaneous hyperreactivity immune dysregulation Chronic with exacerbations and remissions Affects all ages, but more common
More informationDupixent (dupilumab)
Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationPharmacologic Treatment of Atopic Dermatitis
J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc
More information5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema. Part 1. Keys to Adherence: Simplify regimen & Educate
5007 Seminar Advanced Therapeutics: Managing Severe & Refractory Eczema Luz Fonacier, MD Professor of Clinical Medicine State University of New York at Stony Brook Head of Allergy & Training Program Director
More informationUpdate on systemic therapies and emerging treatments How do I choose a systemic agent?
Update on systemic therapies and emerging treatments How do I choose a systemic agent? Amy S. Paller, M.D. Walter J. Hamlin Professor and Chair of Dermatology Professor of Pediatrics Northwestern University
More informationIntegrating Atopic Dermatitis Diagnosis and Treatment Guidelines with Health Plan Algorithms to Optimize Outcomes
Integrating Atopic Dermatitis Diagnosis and Treatment Guidelines with Health Plan Algorithms to Optimize Outcomes John Fox, MD, MHA Senior Medical Director Associate Vice President of Medical Affairs Priority
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationThe Itch That Rashes. Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah
The Itch That Rashes Sarah D. Cipriano, MD, MPH, MS Resident, Dermatology University of Utah 1 Conflict of Interest No conflict of interest Will discuss off label use of medications 2 3 Most likely diagnosis?
More informationChildren s Hospital Of Wisconsin
Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,
More informationDespite heroic leaps in scientific understanding of
Update on Atopic Dermatitis 2018 A look at the pathophysiology of AD, including structural and immunologic contributors, as well as new therapeutic developments with an eye toward breakthroughs on the
More informationATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS. Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine
ATOPIC DERMATITIS: A BLUEPRINT FOR SUCCESS Sierra Wolter MD, FAAD Pediatric Dermatology University of Arizona, College of Medicine THE PLAN Is it atopic dermatitis? What is atopic dermatitis? Guidelines
More informationBrian S. Kim, MD, MTR, FAAD
What s New In the Pathophysiology of Itch? Brian S. Kim, MD, MTR, FAAD Assistant Professor of Dermatology, Anesthesiology, and Pathology and Immunology Co-Director, Center for the Study of Itch Itch is
More information2/25/17. Translating the Evidence: Allergy vs. Dermatology. How can they disagree?! Bias: It doesn t come out in the wash. wash. Precision Medicine
Translating the Evidence: Allergy vs. Dermatology Peter A. Lio, MD, FAAD Assistant Professor Clinical Dermatology & Pediatrics Northwestern University Feinberg School of Medicine How can they disagree?!
More informationTCIs are only available on prescription and are usually started by a dermatology specialist.
(TCIs) What are topical calcineurin inhibitors? Topical calcineurin inhibitors are treatments that alter the immune system and have been developed for controlling eczema. There are two types available:
More informationContact Dermatitis In Atopic Patients
Contact Dermatitis In Atopic Patients Jenny Murase, MD Palo Alto Foundation Medical Group Director of Patch Testing University of California, San Francisco Associate Clinical Professor Disclosures Consultant
More informationRecent insights into atopic dermatitis and implications for management of infectious complications
Mark Boguniewicz, MD Professor, Division of Allergy-Immunology Department of Pediatrics National Jewish Health and University of Colorado School of Medicine Denver, Colorado USA Recent insights into atopic
More informationAtopic Dermatitis. Atopic dermatitis (AD) is very common with a. Going Skin Deep With. Carl s rashes
Focus on CME at Dalhousie University Going Skin Deep With Atopic Dermatitis Scott Murray, MD, FRCP(C), BSc Atopic dermatitis (AD) is very common with a tendency for itching and inflammation of the skin.
More informationLead team presentation
Lead team presentation Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] 1 st Appraisal Committee meeting Committee B Chair: Amanda Adler Lead team: Diar Fattah, Danielle
More informationBreakthrough Drugs in Dermatology. Mark Lebwohl, MD
Breakthrough Drugs in Dermatology Mark Lebwohl, MD Sol and Clara Kest Professor And Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai LIFE CHANGING
More informationNovan Announces Promising Clinical Results with SB414
Novan Announces Promising Clinical Results with SB414 In the recently completed Phase 1b trial for atopic dermatitis, clinical efficacy measures were highly correlated with critical and disease-relevant
More informationElizabeth Ann Golden, PA-C
Elizabeth Ann Golden, PA-C Dawes Fretzin Clinical Research Group, LLC Dawes Fretzin Dermatology Group, LLC 8103 Clearvista Parkway, Suite 260 8103 Clearvista Parkway, Suite 220 Indianapolis, Indiana 46256
More informationBioavailability 55% - 77%
Brand Name: Cosentyx Generic Name: secukinumab Manufacturer 1 : Novartis Pharmaceuticals Corporation Drug Class 2,3 : Antipsoriatic Agent, Interleukin-17A Receptor Antagonist Uses: Labeled Uses 1,2,3 :
More informationVitiligo is a skin depigmentation disorder
THERPEUTICS FOR THE CLINICIN Tacrolimus Ointment 0.1% Produces Repigmentation in Patients With Vitiligo: Results of a Prospective Patient Series Emil. Tanghetti, MD The cause of the selective melanocyte
More informationProfessor Rohan Ameratunga Clinical Immunologist and Allergist Auckland
Professor Rohan Ameratunga Clinical Immunologist and Allergist Auckland 16:30-17:25 WS #170: Eczema Management 17:35-18:30 WS #182: Eczema Management (Repeated) Managing ECZEMA A/Prof Rohan Ameratunga
More informationNew Developments in the Treatment of Atopic Dermatitis: Clinical Highlights From Vienna
CME/MOC New Developments in the Treatment of Atopic Dermatitis: Clinical Highlights From Vienna Course Director Emma Guttman-Yassky, MD, PhD Icahn School of Medicine at Mount Sinai New York, New York What
More informationNIH Public Access Author Manuscript J Invest Dermatol. Author manuscript; available in PMC 2015 February 01.
NIH Public Access Author Manuscript Published in final edited form as: J Invest Dermatol. 2014 August ; 134(8): 2071 2074. doi:10.1038/jid.2014.141. A possible role for IL-17A in establishing Th2 inflammation
More informationWhat is Cosentyx (secukinumab)?
What is Cosentyx (secukinumab)? Cosentyx is the first of a new class of medicines called interleukin- 17A (IL- 17A) inhibitors to be approved for the treatment of moderate- to- severe plaque psoriasis,
More informationClinical Review Report
CADTH COMMON DRUG REVIEW Clinical Review Report DUPILUMAB (DUPIXENT) (Sanofi-Aventis Canada Inc.) Indication: Moderate-to-severe atopic dermatitis (AD) Service Line: CADTH Common Drug Review Version: Final
More informationECZEMA SOCIETY OF CANADA ATOPIC DERMATITIS: PATIENT INSIGHTS REPORT MILD-TO-MODERATE DISEASE
ECZEMA SOCIETY OF CANADA ATOPIC DERMATITIS: PATIENT INSIGHTS REPORT MILD-TO-MODERATE DISEASE 1 OVERVIEW OF SURVEY RESULTS INTRODUCTION PATIENT INSIGHTS BY THE NUMBERS: Adult Atopic Dermatitis (AD) In the
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: , VERSION 12.0
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN (RMP) Elidel 10mg/g cream DATE: 23.11.2016, VERSION 12.0 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Eczema mainly affects children
More information75th AAD Annual Meeting
75th AAD Annual Meeting Poster nº 4873 A phase 3 randomized, double-blind, trial comparing the efficacy and safety of the fixed combination calcipotriene 0.005% (Cal) and betamethasone dipropionate 0.064%
More informationAtopic Dermatitis: Therapeutic Challenges
Atopic Dermatitis: Therapeutic Challenges PDA August 14, 2009 Jon Hanifin OHSU, Portland Dominant Concepts in Atopic Dermatitis Allergy / Immunology Era: 1915-2006 The Epidermal Era: 2006---- Barrier dysfunction
More information1 Introduction. Lee T. Zane 1 Matilda H. Hughes
Am J Clin Dermatol (2016) 17:519 526 DOI 10.1007/s40257-016-0204-6 ORIGINAL RESEARCH ARTICLE Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled
More informationA Year Science to Practice Update for the Dermatological Specialist
A Year 2016 2017 Science to Practice Update for the Dermatological Specialist New Frontiers and Pivotal Clinical Advances for the Pathoimmunobiology of Atopic Dermatitis The Translational Path in Atopic
More informationInfectious Complications of Atopic dermatitis. Is AD a skin problem or an immune problem?
Infectious Complications of Atopic dermatitis Peck Y. Ong, MD Associate Professor of Clinical Pediatrics, Division of Clinical Immunology and Allergy, Children s Hospital Los Angeles, Department of Pediatrics,
More informationGlenmark Pharmaceuticals Inc., USA; Glenmark Pharmaceuticals Ltd., India. Icahn School of Medicine at Mount Sinai, New York, NY, USA;
RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, EXPLORATORY, MULTICENTER STUDY OF IN ADULT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS Emma Guttman-Yassky, MD, PhD 1 ; Ana B. Pavel,
More informationApproach to eczema. Hugo Van Bever Department of Pediatrics NUHS - Singapore
Approach to eczema Hugo Van Bever Department of Pediatrics NUHS - Singapore APAPARI workshop, Yangon, October 30, 2016 Eczema in children 1. Atopic dermatitis 2. Constitutional eczema 3. Contact dermatitis
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAn Everyday Guide to Eczema
An Everyday Guide to Eczema By Dr. Kristel Polder, Board-Certified Dermatologist Developed in Partnership with Who is affected by eczema? 32 million people in the US 1 in 5 children 1 in 12 adults *www.eczema.org
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value. Public Meeting May 25, 2017
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness and Value Public Meeting May 25, 2017 Welcome and Introduction Midwest Comparative Effectiveness Public Advisory Council (CEPAC) The Institute
More informationClinico Pathological Test SCPA605-Essential Pathology
Clinico Pathological Test SCPA605-Essential Pathology Somphong Narkpinit, M.D. Department of Pathogbiology, Faculty of Science, Mahidol University e-mail : somphong.nar@mahidol.ac.th Pathogenesis of allergic
More informationAtopic Dermatitis: Clinical Refresh
In this issue: Atopic Dermatitis: Clinical Refresh Asthma Zero Albuterol Refills: 200 Puffs is Enough Safety of Tricyclic Antidepressants in Older Adults Skeletal Muscle Relaxant Quantity Limits FAQ Pharmacy
More informationMedical Dermatology Highlights Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center
Medical Dermatology Highlights 2017 Eric Hossler, MD Program Director, Dermatology Associate, Dermatopathology Geisinger Medical Center I have no relevant financial relationships with commercial interest(s).
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSaturday, April 22, Please complete the preassessment located in your handout before the program begins.
MILD TO MODERATE ATOPIC DERMATITIS: Pathogenesis and Therapeutic Strategies For Improved Outcomes Saturday, April 22, 2017 Please complete the preassessment located in your handout before the program begins.
More informationOptimizing Topical Therapy In Atopic Dermatitis
Optimizing Topical Therapy In Atopic Dermatitis Steven R. Feldman, MD, PhD Professor of Dermatology, Pathology & Public Health Sciences Wake Forest University School of Medicine Winston-Salem, North Carolina,
More informationAssessing and Treating the Patient with Chronic Itch
Assessing and Treating the Patient with Chronic Itch Sonja Ständer, MD sonja.stander@uni-muenster.de Center for Chronic Pruritus Department of Dermatology University Hospital of Muenster Germany Acute
More informationTopical Doxepin Prior Authorization with Quantity Limit Program Summary
Topical Doxepin Prior Authorization with Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1-3 Agent(s) Indication(s) Dosage & Administration Doxepin 5% cream Prudoxin (doxepin) cream 5% KS_PS_Topical_Doxepin_PAQL_ProgSum_AR1018
More informationDupilumab (atopic dermatitis)
IQWiG Reports Commission No. A17-63 Dupilumab (atopic dermatitis) Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab
More informationUsing Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice)
Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice) Patient Case Study in Psoriasis Patient Case Study in Psoriasis William Smith,
More informationDupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks
Dupilumab and Crisaborole for Atopic Dermatitis: Effectiveness, Value, and Value-Based Price Benchmarks Draft Background and Scope November 7, 2016 Background: Atopic dermatitis (eczema) is a chronic/chronically-relapsing
More informationEichenfield: Neonatal Dermatology
What You Need to Know about Pediatric Dermatology Lawrence F. Eichenfield, M.D. Professor of Dermatology and Pediatrics University of California, San Diego Rady Children s Hospital, San Diego Disclosures
More informationTexas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)
Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so
More informationThe Skinny of the Immune System
The Skinny of the Immune System Robert Hostoffer, DO, FACOP, FAAP Associate Professor of Pediatrics Case Western Reserve University, Cleveland, Ohio Overview 1. Immune system of the skin 2. Immune Players
More informationItchy, Scratchy, Red and Patchy: Derm tips for primary care. Robert Gniadecki, MD
Itchy, Scratchy, Red and Patchy: Derm tips for primary care Robert Gniadecki, MD Faculty/Presenter Disclosure Faculty: Robert Gniadecki Relationships with financial sponsors: Grants/Research Support: N/A
More informationOverview of the Last Decade Inflammatory Skin Diseases. Mark Lebwohl, MD
Overview of the Last Decade Inflammatory Skin Diseases Mark Lebwohl, MD ProfessorAnd Chairman Kimberly and Eric J. Waldman Department of Dermatology Icahn School of Medicine at Mount Sinai Disclosure Mark
More informationDupilumab for treating adults with moderate to severe atopic dermatitis [ID1048]
Dupilumab for treating adults with moderate to severe atopic dermatitis [ID1048] Thank you for agreeing to give us your organisation s views on this technology and its possible use in the NHS. You can
More information